Outlook Therapeutics CEO discusses Lytenava FDA approval and U.S. launch
Tweet Send to a Friend
Outlook Therapeutics, Inc. (Nasdaq: OTLK) announced that Chief Executive Officer Bob Jahr participated in a Virtual Investor CEO Connect segment ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


